THRB and metabolic dysfunction-associated steatohepatitis: Additionally, the THRβ agonist resmetirom has recently been granted expedited approval by the FDA for the treatment of MASH fibrosis based on favorable findings from the registrational phase 3 MAESTRO-NASH study 261.